CraniUS Therapeutics LLC, a private neurotechnology company, recently disclosed that it has secured $20 million in Series B funding. This substantial amount is intended to expedite the advancement of NeuroPASS™, a groundbreaking project designed to enable direct therapeutic access beyond the blood-brain barrier.